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PURPOSE: To detect seroconversion of hepatitis B vaccine and antibody waning 3 years after vaccination in children immunized
according to the World Health Organization schedule and its relationship to the mother’s serostatus during pregnancy.
METHODS: A serological study was carried out in São José dos Campos. Blood samples from pregnant women were taken for
hepatitis B marker serology. To evaluate seroconversion in infants born to these women, serology was performed 1 month after
they were vaccinated with recombinant vaccine. Another group of children was evaluated 3 years after being immunized.
RESULTS: Among 224 pregnant women, 0.9% were positive for hepatitis B surface antigen, 8.0% for antibodies to the surface
antigen, and 4.5% for antibodies to the virus core. Seroconversion among 174 infants was as follows: absent in 18 children
(10.35%), low level in 15 (8.62%), intermediate level in 26 (14.94%), and a high level (good response) in 115 (66.09%). Antibody
positivity after 3 years was as follows: absent in 8 children (7.92%), low level in 51 (50.5%), intermediate level in 20 (19.8%), and
high level in 22 (21.78%). Considering the age that the vaccine was administered, a significant proportion of non-seroconverters
was found among children who had received the complete 3-dose schedule before 9 months (P = 0.023). Another factor that
significantly contributed to the lack of seroconversion was the presence of any serological marker for hepatitis B during pregnancy
(P = 0.044).
CONCLUSIONS: Data gathered in this work show that the immunization schedule for hepatitis B in low or moderate prevalence
areas should be revised in order to optimize seroconversion.
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INTRODUCTION
Hepatitis B is one of the world’s most serious infec-
tious diseases. It is estimated that over 350 million people
worldwide are chronic hepatitis B virus (HBV) carriers.1,2
Studies show that of all infected persons, 25% have
acute hepatitis with jaundice, and 6% to 10% have chronic
hepatitis.3 Of them, 40% die each year from HBV-related
liver diseases in the USA.3,4
Between 35% and 40% of all HBV infections diagnosed
worldwide every year result from vertically transmitted
cases. The risk of infecting their children is increased
among women found seropositive for both hepatitis B sur-
face antigen (HBsAg) and precore antigen (HBeAg), an in-
dicator of high HBV titers.5 In an attempt to reduce the
spread of this virus, in 1991, the WHO recommended the
introduction of HBV vaccination into the Programme of
Immunization in all countries.6
The prevalence of hepatitis B is variable around the
world.7 It is greater in high population density areas, such
as south-east Asia and sub-Saharan Africa, and in isolated
areas, such as Alaska, the Amazon, and some islands of the
Pacific Ocean.8-10
In Brazil, the prevalence is moderate (2% to 7% in most
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part of the country), with the peak of infections occurring
around 25 years of age.11 But in the Amazon, some authors
have found a prevalence of 24.6% to 61.79%.9,10
According to the Brazilian Health Authority, hepatitis
B vaccine was officially used for the first time in 1989 dur-
ing a National Vaccination Day in an endemic area of east-
ern Amazon forest.
Since 1992, the Brazilian Health authority has imple-
mented the vaccine program, giving priority to endemic
areas, such as the States of Acre and the Amazon and for
high-risk groups, such as persons with occupational risk
throughout the country. The States of Santa Catarina,
Espírito Santo, and Paraná implemented the immunization
program against hepatitis B in 1993, and the Federal Dis-
trict implemented it in 1995.
The vaccine was recommended for all states of Brazil
in 1996, targeting all children less than 1 year of age. But,
in 1997 the amount of vaccine was insufficient to immu-
nize according to the 1996 strategy. Only in 1998 did the
stock of vaccines reach an adequate level to guarantee na-
tional coverage, and from then on immunization was regu-
larly achieved, according to health authorities.
Several studies have been conducted in endemic areas
for HBV. In these areas, the dynamics of anti-hepatitis B
antibodies may be influenced not only by vaccination but
also by natural exposure to HBV (natural booster).12 But,
in an area in which the prevalence of HBV decreases, or
with a lower prevalence, such as is found in Southern Bra-
zil, the dynamics of antibodies against surface antigen (anti-
HBs) and the persistence of the protection afforded by the
hepatitis B vaccine may differ from what is observed in
other studies.
The aim of this study was to detect the immediate
seroconversion following HBV vaccination of children 1
month after the last dose for a community attended by the
routine immunization programme of a Basic Health Unit
in Brazil, to determine the seroprevalence of HBV mark-
ers and the prevalence of HBV carriers among pregnant
women, and to determine the anti-HBs levels in the first
cohort of children immunized by the official programme,
in an attempt to contribute to better understanding of the
effects of immunization in a population with moderate
prevalence of hepatitis B infection.
METHODS
2.1. Population and Study Design
This study was carried out in São José dos Campos, a
city of São Paulo State, Brazil. The city has an area of
1,102 km² and is located just north of the Tropic of Capri-
corn (23o 13' 53" latitude south, 45º 51' 21" longitude west),
84 km from São Paulo City, the State capital. Its popula-
tion is about 534,000 habitants, 95.1% in the urban area.
The annual growth rate is around 1.89%.The city of São
José dos Campos is strategically placed along the major
road and rail links between the two largest Brazilian cit-
ies, namely, São Paulo and Rio de Janeiro, and is part of
is known as the Latin America economic development
pole.13
The economic activities in São José dos Campos include
industrial facilities for aircraft, motorcar, pharmaceutical,
telecommunications, health consumables, electro-electron-
ics and photography. The average annual per capita income
is BRL $15,000.00 (circa US $ 7,000.00). The lowest
8.75% of the population have an annual income of
BRL $2,400.00 (circa US $ 1,000.00), and 18.26% have
an income of BRL $ 4,800.00 (circa US $ 2,000.00) per
year.14
This study was performed at the Basic Health Unit
(BHU) of the borough of Campo dos Alemães; it is one of
the 42 BHU in town, and serves approximately 21,800 peo-
ple for assistance with clinical, pediatric and gynecologic
primary care and prenatal care.
To check seroconversion and antibody concentration
against the surface antigen (anti-HBs) a transverse serologi-
cal study was performed with children immunized since
1998, the year in which the official programme was intro-
duced. Two groups were established: the first cohort com-
prised children immunized after 6 months of age, and the
second cohort, with children immunized according to the
current vaccination schedule.
The recent seroconversion study was conducted in chil-
dren born to women who attended in the prenatal program
of the BHU of Campo dos Alemães.
From June 2000, pregnant women selected from a list
of women with a positive b-HCG test were contacted and
invited to participate in this study. A database was built with
their complete names, record numbers, addresses, and pre-
dicted day of delivery. All participants were informed of
the purpose of the study, and a written informed consent
was subsequently obtained.
Blood samples from pregnant women were collected
during the period from August 2000 to June 2001, approxi-
mately 6 weeks before delivery, for determination of HBV
markers.
The newborn babies were examined monthly by the
pediatrician conducting this study (TMR) as part of first-
year pediatric routine. From each child’s record, the weight,
height, and adverse events related to vaccination were re-
corded in our immunization database. These infants were
vaccinated according to the schedule proposed by the Bra-
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zilian Health Authority. One month after the last dose of
hepatitis B vaccine, blood samples were collected from the
children and tested for anti-HBs.
Parents of the children assisted at Campos dos Alemães
who were immunized against hepatitis B from October
1998 until August 2001 were contacted to enter this study,
constituting a group in which we analyzed the antibody
concentration more than 1 year after vaccination.
2.2. Vaccine
The vaccines used routinely in our country are bought,
handled, and administered by central and local health au-
thorities. During this study, the children received any of
these yeast-derived hepatitis B vaccines: Euvax B
recombinant®, LG Chemical Ltda. Pharmaceutical Div.,
Seoul, Korea—241 doses; Engerix-B®, Smithkline
Beecham, Belgium—495 doses; and Hepavax-Gene®, Ko-
rea Green, South Korea—89 doses.
Each dose of this vaccine was given in the musculus
vastus lateralis of right thigh, in a dose of 0.5 mL (10 m.
The vaccine was given during the first month of life and
then 1 month and 6 months after the first dose.
2.3.Blood collection and serology
Blood samples were collected by venipuncture with but-
terfly and syringe designed for children and through a
vacuum collecting system designed for pregnant women.
Samples were left at room temperature for 2 hours and
then centrifuged at 3000 rpm for 15 minutes. Serum was
separated from the clot, then frozen to and preserved at -
20 ºC until being transported to the university laboratory.
Sera were transported to the city of São Paulo inside a
thermal box with recycled ice (Gelo-X®, Adiquima Ind
Com Adit Ltda., SP, Brazil) to keep the temperature be-
tween 2 and 8 ºC, and then stocked in a freezer at -20 ºC,
at the Laboratory of Immunosuppressive Investigation (LIM
01), Department of Pathology, Hospital das Clínicas, São
Paulo University Medical School until laboratory analysis.
Serum was tested by enzyme immunoassay technique,
using commercial kits as follows: HBV surface antigen
(HBsAg) by Murex HBsAg Version 3®(Abbott, UK); anti-
bodies against surface antigen (anti-HBs) by ETI-AB-AUK-
3® (DiaSorin, Italy) and Murex anti-HBs® (Abbott, UK);
and antibodies against core antigen (anti-HBc), using
Hepanostika® anti-HBc Uni-Form (Organon Teknika, Hol-
land).
The variables collected for the study were: (i) gender,
(ii) weight and height at birth and at the last dose of vac-
cine for calculation of body mass index (weight/height2),
(iii) the Capurro value, (the most used method for deter-
mination of the gestational age, in weeks, from clinical and
neurological data), (iv) age of child at first and third dose
of vaccine, (v) vaccine brand(s), (vi) interval between last
dose and blood collection, and (vii) determination of the
HBV markers of the mother (anti-HBs, anti-HBc, and
HBsAg).
2.4. Data management and analysis
Data were collected and organized using a spreadsheet
software (MS-Excel®, MS-Office 97®, Microsoft, USA).
Statistical tests were performed using EPI-INFO version 6.0
STATCALC and EPITABLE modules, CDC, USA &
WHO, Switzerland, and MINITAB version 13.1, Minitab
Inc., USA.
Categorical variables were analyzed by the χ2 test cor-
rected by the Mantel-Haenszel technique where applica-
ble, adopting 5% as the level of significance.
Anti-HBs concentration was analyzed by 1-way
ANOVA to test differences among groups classified by the
time from the last vaccine dose.
RESULTS
From June 2000 to June 2001, 507 pregnant women
were contacted and invited to participate in this study.
Blood samples were taken from 224 pregnant women.
Among the 224 pregnant women, the following distri-
bution of ages was observed: 24 (10.71%) were 14 through
17 years of age; 60 (26.78%) were 18 through 21 years;
51 (22.77%) were 22 through 25 years; 45 (20.09%) were
26 through 29 years; 23 (10.27%) were 30 through 33
years; 12 (5.36%) were 34 through 37 years; and 9 (4.02%)
were 38 through 41 years of age.
Regarding the questionnaire answered by those 224
pregnant women, the following information was found: pre-
vious history of diagnosed hepatitis B infection (0.4%),
hepatitis B infection in family members (3.1%), history of
alcoholism (0.4%), history of previous blood transfusions
(4.0%), and history of use of non-intravenous illicit drugs
(4.9%). None of the patients admitted a history of previ-
ous use of intravenous illicit drugs. Two patients (0.9%)
were vaccinated against hepatitis B because they had jobs
that require this immunization.
Seroprevalence among pregnant women was found to
be 8.0% for anti-HBs (18 in 224), 4.5% for anti-HBc (10
in 224), and 0.9% for HBsAg carriers (2 in 224).
The 224 participants delivered 226 newborns. Of them,
6 (2.7%) died, 3 (1.3%) had the permission to enter the
study suspended by their parents, 13 (5.8%) moved from
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the city, and 3 (1.3%) gave wrong addresses.
In the final account, 174 children were sampled and se-
rology was performed. All of them received the complete
course of hepatitis B vaccination.
Details of the time of administration of the first vac-
cine dose were available for these 174 children as follows:
74 (42.5%) received the vaccine within 48 hours after birth
and 100 (57.5%) had their first dose after this time. This
occurred because the vaccine is administrated soon after
birth in only 1 hospital. The other children received their
first immunization at the Health Basic Unit.
Among the 174 infants, 85 (48.8%) were female and
89 (51.2%) were male. The distribution of race was as fol-
lows: 13 (8.44%) black; 96 (62.34%) white; and 45
(29.22%) mulatto.
Vaccinees were observed for fever, injection site reac-
tions, and systemic complaints. No side effects of the vac-
cine were observed, with only minor limited local reactions
at the site of administration.
Seroconversion was as follows: absent in 18 infants
(10.35%), low level (10 to 100 mIU/mL) in 15 (8.62%),
intermediate level (101 to 500 mIU/mL) in 26 infants
(14.94%), and high level (good response) ( > 501 mIU/mL
) in 115 vaccinees (66.09%). The average concentration was
740.87 mUI/mL (± 524.79 mUI/mL).
Cross tabulation of children’s serostatus for anti-HBs
and their mother’s positivity for any HBV serological
marker presented a significant association (P = 0.044),
showing that seroconversion was lower in children from
positive mothers (Table 1).
No significant difference was found between the anti-
body response to anti-HBV vaccine and weight and height
(body mass index) at the time of the third dose.
To check the persistence of anti-HBs concentration in
the group of children immunized after 1998 by the national
programme, 101 children 1 through 4 years old were sam-
pled among 1520 children who had received the HBV vac-
cine in Campo dos Alemães BHU. Among those 101 chil-
dren, 49 (48.5%) were girls and 52 (51.5%) were boys.
Of them, 32 children were from the first group vacci-
nated in 1998 (first cohort), sampled after an average of
32 months from the last vaccine dose. Data on anti-HBs
antibody concentration was obtained in 69 children sam-
pled 11 to 30 months after the last dose of HBV vaccine
(second cohort).
The antibody response to hepatitis B vaccine of the first
cohort was as follows: no one was negative for anti-HBs,
14 (43.8%) had low levels of antibodies (10 to 100 mIU/
mL), 9 (28.1%) had intermediate levels (101 to 500 mIU/
mL), and 9 (28.1%) had high levels (good responses) (>
501 mIU/mL). Antibody concentration varied between
35.19 to 1973.87 -mUI/mL. The mean antibody concen-
tration was 406.38 mUI/mL (±504.50 mUI/mL).
The serological responses of the second cohort was as
follows: antibodies were absent in 8 (11.6%), 37 (53.6%)
had low levels (10 to 100 mIU/mL), 11 (15.9%) had inter-
mediate levels (101 to 500 mIU/mL), and 13 (18.8%) had
high levels (good responses) (> 501 mIU/mL). Antibody
concentration varied between 1.56 to 1257.41 mUI/mL.
The mean antibody concentration was 218.50 mUI/mL
(±304.94 mUI/mL).
Table 2 shows the results of the 3 groups studied for
seropositivity for anti-HBs.
To analyze antibody waning from the last dose of vac-
cination and the seroconversion related to age, data from
the 3 groups were added together to form a single group.
If we consider the age, in months, at which the chil-
dren received the first dose of the hepatitis B vaccine, we
Table 1 - Mothers’ serostatus versus children’s seroconversion
Age (in months) Anti-HBs<10 UI/L Anti-HBs>10 UI/L Total
≤ 7 22 (12.5%) 154 (87.5%) 176
> 7 4 (4.1%) 95 (95.9%) 99
Total 26 (9.45%) 249 (90.55%) 275
χ2 = 5.3 (P = 0.022)  corrected by Mantel-Haenzel.
Table 2 - Seropositivity to anti-HBs for the 3 groups of children studied
Age (in months) Anti-HBs<10 UI/L Anti-HBs>10 UI/L Total
6.5 17 (15.04%) 96 (84.96%) 113
6.5 to 9 8 (6.56%) 114 (93.44%) 122
> 9 1 (2.5%) 39 (97.50%) 40
Total 26 (9.45%) 249 (90.55%) 275
χ2 = 7.58  (P = 0.023).
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observe that the likelihood of seroconversion increases if
it is given after the second month of life (Table 3).
Moreover, if we categorize the children by the age at
which they received the third dose of HBV vaccine, we ob-
serve that the seroconversion also increases if this last dose
is given after the 6.5 months of age (Table 4). We elected
to stratify into 3 levels, namely: up to 6.5 months, 6.5
though 9 months, and after 9 months. This strategy stems
from the age at which the first dose of hepatitis B vaccine
was given: if the child received the first dose soon after
birth, he/she received the last dose around 6 months of age;
but if the first dose was administered after the second month
of life, the last dose was given after 9 months of age. It
should be noted that the interval between the doses is speci-
fied, and these doses tend to be administered in the inter-
val proposed or later, never in a shorter period of time.
When all the children were stratified into 2 groups by
the age at which they received the third HBV vaccine dose,
using 7 months of age as the cut-off point, a significant
difference in seroconversion in favor of the older children
(P = 0.022) was observed. In this case, children immunized
by the official proposed calendar did not benefit as much
as those for whom immunization was delayed to a later age
(Table 5).
We classified time elapsed after last dose of anti-HBV
vaccine was given into 5 categories, namely: 1 through 1.5,
1.6 through 3, 3.1 through 12, 12.1 through 24, and 24.1
through 36 months. The analysis of variance showed that
there is a significant difference among these groups in re-
spect to anti-HBs concentration (P < 0.001) (Figure 1).
DISCUSSION
The main objective of HBV vaccination is to prevent
the chronic carrier state and its associated morbidity and
mortality, especially in areas where the prevalence is higher,
posing risks to the infants.15 The vast majority of reports
have been about the experience with HBV vaccine in these
types of areas.
There are few studies that adequately address the ef-
fect of HBV vaccination in areas where the prevalence is
moderate to low, and therefore the circulation of the virus
is correspondingly low, which may cause the outcomes of
Table 5 - Age at the third HBV vaccine dose versus seroconversion, by stratification into 2 age groups
Mother’s serostatus for HBV markers Children negative for anti-HBs Children positive for anti-HBs Total
negative 14(8.86%) 144(91.14%) 158
positive 4(25%) 12(75%) 16
Total 18(10.35%) 156(89.65%) 174
χ2 = 4.0 (P = 0.044) corrected by Mantel-Haenzel.
Table 4 - Age at the third HBV vaccine dose versus
seroconversion, by stratification into 3 age groups
Seropositivity
GROUP Anti-HBs<10 UI/L Anti-HBs>10 UI/L
Recent cohort 18 (10.3%) 156 (89.7%)
First cohort 0 (0%) 32 (100%)
Second cohort 8 (11.6%) 61 (88.4%)
Table 3 - Age at the first HBV vaccine dose versus seroconversion
Age (in months) Anti-HBs<10 UI/L Anti-HBs>10 UI/L Total
< 2 26 (10.84%) 214 (89.16%) 240
2 to 12 0 (0%) 35 (100%) 35
Total 26 (9.45%) 249 (90.55%) 275
χ2 = 4.18 (P = 0.041) corrected by Mantel-Haenzel.
Figure 1 - Box-plot of anti-HBs concentration related to time elapsed after
last dose of HBV vaccine - dots represent the average antibody concentration
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the immunization in the long run to be potentially differ-
ent from outcomes in countries or areas with a high HBV
prevalence.
The optimal age for immunizing a population must take
into account some characteristics of the target population,
such as the best seroconversion time, the age-dependent
force of infection, as well as antibody waning after vacci-
nation and its potential effect on weakening immunity, and
consequently the necessity of re-vaccination schemes.
The HBV prevalence in Southern Brazil is low to mod-
erate. As shown by our data, 1% of pregnant women are
infected and carrying HBV, being a risk for vertical or peri-
natal transmission. The prevention this type of transmis-
sion seems to have been improved by serological screen-
ing carried out since the year 2001 during the prenatal of-
ficial programme. Women positive for HBV and their
newborns are treated with hepatitis B immunoglobulin and
vaccination as soon as the baby is delivered.
Considering this epidemiological scenario, it is perti-
nent to question the practice of vaccinating all infants soon
after birth without investigating seroconversion at this age,
or the efficacy of the resulting immunity as protection
against hepatitis B infection.
Seroconversion studies have shown a good response
among newborns and infants. In a recent study done in São
Paulo State, Brazil, full-term newborns had a high rate of
seroconversion following vaccination with recombinant
hepatitis B.16 In that study, 98% (95% CI = 91.6-99-9)
seroconverted, with 1.8% having low (<10 mIU/mL),
26.3% having intermediate (10-100 mIU/mL), and 71.9%
having good (>100 mIU/mL) anti-HBs titers, with a mean
anti-HBs titer of 537.5 mIU/mL. Our experience with the
immune response in full-term babies is different, in that
we found a greater percentage with low antibody levels and
a higher percentage of good responses. In our study, we
found that 1 month after the last HBV vaccine was given,
seroconversion was low (<10 mIU/mL) in 10.35%, inter-
mediate (10-100 mIU/mL) in 8.62%, and high (good) (>
100 mIU/ml) in 81.03% of the neonates, with a mean con-
centration of 740.87 mIU/mL (± 524.79 mIU/mL).
The previous study cited above was conducted in an
University Hospital, where subjects and materials are un-
der better control when compared with native community
with its populational heterogeneities in terms of immuno-
logical response and application of vaccination procedures.
This could possibly explain differences in the proportion
of low responders to Hepatitis B vaccine.
It must be noted that vaccine products come from dif-
ferent vaccine laboratory manufacturers and countries. Al-
though this fact may have introduced heterogeneity in im-
munological response among vaccinees, our results are still
valid and relevant for evaluating the actual herd immunity
obtained from the immunization programme. In other
words, health authorities must be aware that varying vac-
cine products to be applied in immunization will influence
the population protection against a given disease. Conse-
quently, it is important to keep a surveillance program for
evaluating the real outcome of a vaccination strategy.
It is important to emphasize that seroconversion ob-
tained in this routine immunization service was around 90%
among children who had received the HBV vaccine before
9 months of age. This phenomenon could result in an ac-
cumulation in the future of 10% per year of individuals sus-
ceptible to HBV infection, exposing this population to a
greater risk, because they believe they are immunized.
Our data indicates that seroconversion is maximized af-
ter 9 months of age.
Moreover, considering that there is a significant decay
in the antibody concentration, it is possible that individu-
als immunized early in life will be susceptible and at in-
creased risk when adolescents or during adulthood, when
the incidence of hepatitis B is greater.
In conclusion, it seems to be inadequate to maintain the
immunization programme against hepatitis B soon after
birth as it is presently scheduled. It is our opinion that HBV
vaccine should be given after 9 months of age in low and
moderate HBV-endemic areas.
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RESUMO
Ribeiro TM, Azevedo RS. Soroconversão vacinal da
hepatite B em crianças no primeiro ano de vida e sua
relação com a soropositividade das mães em uma
comunidade de São José dos Campos. CLINICS.
2006;61(5):387-94.
OBJETIVO: Determinar a soroconversão vacinal da
hepatite B em crianças no primeiro ano de vida e sua
relação com a soropositividade das mães e avaliar a
concentração de anticorpos 3 anos após a vacinação.
MÉTODOS: Estudo sorológico, realizado na cidade de
São José dos Campos com amostras de sangue coletadas
de gestantes para testar marcadores de Hepatite B. Para
avaliar a soroconversão em crianças nascidas dessas
mulheres, realizou-se sorologia mês após a última dose de
vacina. Em outro grupo de crianças, imunizadas há 3 anos,
foi feita a mesma sorologia.
RESULTADOS: Entre 224 gestantes, 0,9% foram positivas
para o antígeno de superfície, 8,0% para anticorpos contra
este antígeno e 4,5% para anticorpos contra o “core” vi-
ral. A soroconversão de 174 crianças, um mês após a última
dose da vacina, foi ausente em 18 crianças (10,35%), baixa
em 15 (8,62%), intermediária em 26 (14,94%), e houve boa
resposta em 115 (66.09%). A soropositividade de 101
crianças vacinadas há 3 anos, foi ausente em 8 (7,92%),
baixa em 51 (50,5%), intermediária em 20 (19,8%), e alta
concentração de anticorpos em 22 (21,78%). Considerando
a idade da vacinação, encontrou-se uma proporção
significante de crianças soronegativas entre vacinadas antes
dos 9 meses (p=0,023). Contribuiu significativamente para
a baixa soroconversão a positividade de qualquer marcador
sorológico durante a gravidez (p=0,044).
CONCLUSÃO: Os dados reunidos neste trabalho mostram
que o calendário vacinal para a Hepatite B em regiões de
baixa ou moderada prevalência poderia ser revisado para
otimizar a soroconversão.
UNITERMOS: Hepatite B. Soroconversão. Soropre-
valência. Vacinação. Declínio da concentração de
anticorpos.
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